Nektar Therapeutics (NKTR) Misses Q1 EPS by 6c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $63.65 +2.61%
EPS Growth %: +26.6%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
CGEH, NAKA, APOG, More
EPS Growth %: +26.6%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.37), $0.06 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $19.8 million versus the consensus estimate of $38.68 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- Benchmark Reiterates Buy Rating on Kura Sushi USA Inc. (KRUS) Ahead of Q3 Print
- UBS Downgrades Grand Korea Leisure (114090:KS) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
